SCHEMBL1920437

SCHEMBL1920437

O=[C]c1ccc2c(ccc3ccccc32)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.61
CYP1B1 Q16678 2/20 0.61
CYP1A1 P04798 1/20 0.61
ALDH1A1 P00352 4/20 0.54
HSD17B10 Q99714 3/20 0.54
HIF1A Q16665 1/20 0.54
HPRT1 P00492 4/20 0.52
CYP2A6 P11509 1/20 0.50
TSHR P16473 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
HPGD P15428 2/20 0.47
MAPT P10636 1/20 0.47
ERBB2 P04626 1/20 0.44
FYN P06241 1/20 0.44
MAOA P21397 1/20 0.44
ACHE P22303 1/20 0.44
AHR P35869 1/20 0.44
PAX8 Q06710 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1920223 0.89 ALDH1A1 (0.56) CYP1A2CYP1B1CYP1A1ALDH1A1HSD17B10
SCHEMBL22288270 0.83 CYP1A2 (0.78) CYP1A2CYP1B1CYP1A1ALDH1A1HSD17B10
SCHEMBL69325 0.82 CES2 (0.43) CYP1A2CYP1B1CYP1A1ALDH1A1HSD17B10
SCHEMBL1921032 0.80 ALDH1A1 (0.44) CYP1A2CYP1B1CYP1A1ALDH1A1HSD17B10
SCHEMBL11815018 0.79 CYP1B1 (0.61) CYP1A2CYP1B1CYP1A1ALDH1A1HSD17B10
SCHEMBL1344052 0.79 CA1 (0.67) CYP1A2CYP1B1CYP1A1ALDH1A1HSD17B10
SCHEMBL12310187 0.78 CA1 (0.65) CYP1A2CYP1B1CYP1A1ALDH1A1HSD17B10
SCHEMBL12320895 0.78 CA1 (0.65) CYP1A2CYP1B1CYP1A1ALDH1A1HSD17B10
SCHEMBL9478531 0.78 CA1 (0.38) CYP1A2CYP1B1CYP1A1ALDH1A1CA1
SCHEMBL4022260 0.77 ASIC3 (0.33) CYP1A2CYP1B1CYP1A1CYP2A6CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009115644-A1 LANTHANIDE(III) CHELATES COMPRISING BETA-DIKETONES AND CONJUGATES DERIVED THEREOF WALLAC OY (FI) 2009-09-24 WO claimed
CN-116813979-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2023-09-29 CN disclosed
CN-112839988-B Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2023-06-06 CN disclosed
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-12-23 US disclosed
EP-3858909-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-08-04 EP disclosed
CN-112839988-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2021-05-25 CN disclosed
US-8394974-B2 Process for producing optically active chromene oxide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-03-12 US disclosed
EP-1718629-B1 Benzopyran compounds useful for the treatment of arrhytmia NISSAN CHEMICAL IND LTD (JP) 2012-12-26 EP disclosed
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
EP-1590491-B1 ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS BASF SE (DE) 2011-06-01 EP disclosed
EP-1590492-A1 TANNING AGENTS AND PRESERVATIVES BASF AKTIENGESELLSCHAFT (DE) 2005-11-02 EP disclosed
EP-1590491-A1 ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS BASF Aktiengesellschaft (DE) 2005-11-02 EP disclosed
WO-2005090357-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-09-29 WO disclosed
EP-1552828-A1 THROMBOPOETIN RECEPTOR ACTIVATOR AND PROCESS FOR PRODUCING THE SAME Nissan Chemical Industries, Ltd. (JP) 2005-07-13 EP disclosed
WO-2005031007-A1 METHOD FOR THE PRODUCTION OF LEATHER AND SEMIFINISHED PRODUCTS, AND FORMULATIONS THAT ARE SUITABLE THEREFOR BASF AKTIENGESELLSCHAFT (DE) 2005-04-07 WO disclosed
WO-2004067782-A1 TANNING AGENTS AND PRESERVATIVES BASF AKTIENGESELLSCHAFT (DE) 2004-08-12 WO disclosed
WO-2004067781-A1 ADDUCTS BASED ON CYCLIC COMPOUNDS AND THE USE THEREOF AS TANNING AGENTS AND CURING AGENTS BASF AKTIENGESELLSCHAFT (DE) 2004-08-12 WO disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF NOC2L, RIF1, NAP1L1 CYP1A2 3026/4885CYP1B1 2753/4885CYP1A1 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.